Abstract 931P
Background
Currently, there is a paucity of validated deep learning methodologies for predicting short-term efficacy in locally advanced nasopharyngeal carcinoma (NPC), both domestically and internationally. Furthermore, advanced techniques such as 2.5D feature extraction and Transformer model establishment remain underexplored in this context.
Methods
MRI images from locally advanced NPC patients diagnosed at two centers between July 2020 and June 2023 were retrospectively collected. Three state-of-the-art (SOTA) models (SegResNet, Unet, and UnetR models) were employed for automatic segmentation of all regions of interest (ROIs), thus generating an automatic segmentation model. Leveraging 2.5D deep learning techniques, tumor image features were extracted and integrated into a transfer learning framework. Subsequently, a Transformer-based model was designed, integrating all individual patient features. Three models were established: a clinical model, a Transformer model, and a fusion model. The predictive performance of these models was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).
Results
Among the three models, the Transformer model demonstrated superior predictive performance in both the testing (AUC = 0.957) and validation cohorts (AUC = 0.893) compared to the clinical model. Moreover, the fusion model generally matched or surpassed the performance of the Transformer model, particularly in the testing cohort with an AUC of 0.874, indicating that the integration of clinical data with advanced machine learning models can enhance predictive capability.
Conclusions
The fusion model, which combines machine learning with clinical factors, exhibits promising efficacy in predicting short-term outcomes in locally advanced NPC patients following synchronous chemoradiotherapy.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1025P - Fully intravenous delivery regimen of oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) in patients with advanced solid cancers
Presenter: Santeri Pakola
Session: Poster session 03
1026P - Updated results from the phase I 1456-0001 study for intratumoral (IT) VSV-GP (BI 1831169) in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster session 03
1027P - First results for intravenous (IV) VSV-GP (BI 1831169) in patients (pts) with advanced solid tumors from the 1456-0001 study
Presenter: Marc Oliva Bernal
Session: Poster session 03
1028P - A phase I study of personalized KSX01-TCRT therapy for advanced solid tumor and its mechanisms
Presenter: Shuhang Wang
Session: Poster session 03
Resources:
Abstract
1029P - Preclinical development of TCR-modified T cell therapies against mutated KRAS
Presenter: Hugh Salter
Session: Poster session 03
1030P - Survival rates in high-risk neuroblastoma patients undergoing anti-GD2 immunotherapy: A single arm meta-analysis and systemic review
Presenter: Lorena Escalante Romero
Session: Poster session 03
1032P - Tumor-infiltrating lymphocytes with inducible membrane-tethered IL-12 cultured in optimized media exhibits superior anti-tumor activity
Presenter: Patrick Innamarato
Session: Poster session 03
1033P - Anti-tumor efficacy and safety of conditionally activated armored CAR-T cells against gastrointestinal tumors
Presenter: Zhihong Huang
Session: Poster session 03
1034P - Preclinical development of genetically modified tumor-infiltrating lymphocytes using biopsy samples from liver cancer patients
Presenter: Mingyu Liu
Session: Poster session 03
1035P - A new IL-6 inducing mechanism in cancer with new therapeutic possibilities
Presenter: Leif Håkansson
Session: Poster session 03